---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060865"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:22:05.572705+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cellectar Q1 net loss $0.74/share; cash $40M; WM study data in June

## Summary
- Net loss of $21.6M ($0.74/share) in Q1 2024 vs $8.6M ($0.76/share) in Q1 2023; cash $40.0M.
- CLOVER WaM pivotal study met primary endpoint: major response rate 61%; full data in June; NDA submission on track for H2 2024.
- Cash $40.0M as of March 31, 2024, expected to fund operations into Q4 2024; net cash used in operations ~$13M in Q1.
- Phase 1b pediatric high-grade glioma study enrolled first patient; data expected H2 2024.
- Preclinical data for alpha-emitting CLR 121225 in pancreatic cancer; phase 1 planned by Q1 2025.

## SEC filing metadata
- accession: 0001104659-24-060865
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924060865/0001104659-24-060865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924060865/tm2414381d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060865
- JSON: https://secwatch.observer/filing/0001104659-24-060865.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060865.txt

## Key facts
- Earnings Releases
  Cellectar Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income The net loss attributable to common stockholders for the three months ended March 31, 2024, was ($21.6) million, or $(0., EPS $(0.74) per share.
  - Period: the quarter ended March 31, 2024
  - Net income: The net loss attributable to common stockholders for the three months ended March 31, 2024, was ($21.6) million, or $(0.
  - EPS: $(0.74) per share
  - Result: reported results
  source text: Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465924060865/0001104659-24-060865-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.